The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
Approval Alert | Tislelizumab in Metastatic Esophageal Squamous Cell Carcinoma
Patients with unresectable or metastatic esophageal squamous cell carcinoma and higher PD-L1 expression may benefit from treatment with tislelizumab, according to Syma Iqbal, MD.
Results from the phase 3 RATIONALE 302 trial led to the approval of tislelizumab for patients with unresectable or metastatic esophageal squamous cell carcinoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Sacituzumab Tirumotecan Improves Survival in Second-Line EGFR+ NSCLC
2
Lenvatinib/Everolimus Beats Cabozantinib in Phase 2 RCC Study
3
Pembrolizumab Combo Significantly Improves PFS/OS in Recurrent PROC
4
Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC
5
